EGFR and neoplasm: In summary, GFHPD consumption efficiently reduced PD-1 and PDL-1 immune-checkpoint protein expression to a comparable extent as anti-EGFR Ab therapy, suggesting both therapeutic regimens to boost anti-tumor T-cell responses.